GeoVax Labs is a biotechnology business based in the US. GeoVax Labs shares (GOVX) are listed on the NASDAQ and all prices are listed in US Dollars. GeoVax Labs employs 17 staff and has a trailing 12-month revenue of around $300,677.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.87 |
|---|---|
| 52-week range | $1.09 - $11.18 |
| 50-day moving average | $3.41 |
| 200-day moving average | $3.26 |
| Wall St. target price | $42.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-13.31 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.87 from 2024-09-05
| 1 week (2024-08-30) | -16.41% |
|---|---|
| 1 month (2024-08-06) | 115.00% |
| 3 months (2024-06-06) | 125.00% |
| 6 months (2024-03-06) | 80.00% |
| 1 year (2023-09-06) | 567.13% |
|---|---|
| 2 years (2022-09-06) | 251.82% |
| 3 years (2021-09-03) | 5.63 |
| 5 years (2019-09-06) | 764 |
| Revenue TTM | $300,677 |
|---|---|
| Gross profit TTM | $81,526 |
| Return on assets TTM | -134.35% |
| Return on equity TTM | -362.39% |
| Profit margin | 0% |
| Book value | $-0.55 |
| Market Capitalization | $33.4 million |
TTM: trailing 12 months
We're not expecting GeoVax Labs to pay a dividend over the next 12 months.
You may also wish to consider:
GeoVax Labs's shares were split on a 1:15 basis on 30 January 2024. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your GeoVax Labs shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for GeoVax Labs shares which in turn could have impacted GeoVax Labs's share price.
Over the last 12 months, GeoVax Labs's shares have ranged in value from as little as $1.0901 up to $11.18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while GeoVax Labs's is 3.103. This would suggest that GeoVax Labs's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put GeoVax Labs's beta into context you can compare it against those of similar companies.
GeoVax Labs, Inc. , a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U. S.
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.